TexasMarvL
2 days ago
K934473 - May 1st 2024. Title updated to "Evaluation of Dry Eyes"
https://www.myhealthtoolkit.com/web/public/brands/medicalpolicy/external-policies/evaluation-of-dry-eyes/
History From 2016 Forward
05/01/2024 Annual review, no change to policy intent. Updating rationale and references. Title updated to Evaluation of Dry Eyes.
01/09/2024 Updating review to April. No other changes.
10/31/2023 Moving Review to January. No other changes made.
04/10/2023 Corrected review date from 04/01/2023 to 12/01/2023 to coincide with Avalon review.
04/07/2022
Annual review, no change to policy intent. Updating rationale and references and adding table of terminology.
04/05/2021
Annual review, no change to policy intent. Updating rationale and references.
10/01/2020
Interim review, updating policy with medical necessity criteria: Testing of tear osmolarity in patients suspected of having dry eye IS MEDICALLY NECESSARY to aid in determining the severity of dry eye disease as well as to monitor effectiveness of therapy. Also updating description, rationale and references.
04/14/2020
Annual review, no change to policy intent.
04/03/2019
Annual review, no change to policy intent, but, expanding specificity of tests that are not medically necessary. Also updating coding.
04/17/2017
Interim review, month of review changed, no other changes.
12/04/2017
Interim Review. Updated policy section. No other changes made.
10/19/2017
Annual review, no change to policy.
04/26/2017
Updated category to Laboratory. No other changes.
12/05/2016
New Policy
TexasMarvL
2 months ago
I'm going to repeat myself.
BOTTOM LINE:
AXIM and MJNA insiders have control over ALL the AXIM assets. Verséa Ophthalmics is building their business on the foundation of the exclusive marketing agreement for three of the AXIM Dry Eye Disease Tear based Point-of-Care tests.
MY OPINION:
Personally I have been a "big" buyer below a penny in the last month or two. This is not investment advice. Penny stocks can have a high level of volatility. There is a risk of losing everything invested in AXIM. Don't invest money needed for food or rent or happiness.
STANDING ON A LIMB OPINIONS:
If my analytical brain studies the two paragraphs above I arrive at the following conclusion.
First, AXIM is out of cash and possibly getting closer to running out of insider credit. AXIM & MJNA still control 100% of the AXIM assets. Someone with deep pockets allows the party to continue. When will the credit cards be cut in half?
Second, we know Verséa Ophthalmics has an exclusive merchandising agreement with AXIM for three AXIM tests, 2 of which are FDA cleared.
In my opinion, it makes a lot of sense for Verséa Ophthalmics to have more control over their own future. That would imply shared ownership over the assets controlled by a financially struggling AXIM. Based on nothing but opinion, I believe some form of merger is in progress behind the scenes. Possibly a stock for stock (no cash) merger that allows all parties to retain ownership but also allows Verséa Health shared ownership over the AXIM portfolio of products. In this scenario everyone wins including retail investors. Verséa Health can IPO the consolidation and raise needed money for the combined business.
Maybe farfetched. 100% opinion.
My theory is based on an analytical exercise focused on the needs and assets of the two companies joined by the marketing agreement. On paper it could work out for everyone if a merger can agree on the value of each business.
Hope this limb doesn't break.
Not investment advice.
TexasMarvL
2 months ago
$53,000 in Q1 revenue. This is bare bones revenue and according to my original ballpark math, there was $45,000 in new start-up revenue and only about $8000 in re-order revenue.
This actually makes sense. It takes time to get staff trained on the new tests. It takes time to get staff focused on selling the new tests.
This is my original ballpark math
15×300×$10=$45,000 for initial start-ups in Q1.
One new location per week.
15 locations
300 initial tests ordered at startup.
AXIM gets $10 per test
Reorders per location per month may be between 50 and 150 tests. If we can estimate 100 tests per location per month it makes the math easier.
15×100×3×$10=$45,000.
15 locations
100 tests re-ordered each month.
3 months in a quarter.
AXIM gets $10 per test